EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries

By K. Kotseva, D. Wood, G. Backer, D. Bacquer, K. Pyörälä, U. Keil. European Journal of Cardiovascular Prevention & Rehabilitation, 2009

836 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/5c893ea7aeda90a97c965577966b82e70b3dc47d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

In Surgery

Citations in the corpus

2016 European Guidelines on cardiovascular disease prevention in clinical practice. (2016, background): “The importance of starting appropriate prevention before hospital discharge cannot be overemphasized, as prevention treatment tends to decrease rather than increase post-hospitalization, with proportions of patients on appropriate therapy declining over time and patients not reaching risk factor tar”
2016 European Guidelines on cardiovascular disease prevention in clinical practice (2016, background): “The importance of starting appropriate prevention before hospital discharge cannot be overemphasized, as prevention treatment tends to decrease rather than increase post-hospitalization, with proportions of patients on appropriate therapy declining over time and patients not reaching risk factor tar”
European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) (2012, neutral): “The human and economic arguments in favour of CVD prevention were recently estimated by the National Institute for Health and Clinical Excellence (NICE)(32) as overwhelmingly positive, and many committees from other countries have almost the same views.(33) According to the report of NICE, implement”
2016 European Guidelines on cardiovascular disease prevention in clinical practice (2017, neutral): “The importance of starting appropriate prevention before hospital discharge cannot be overemphasized, as prevention treatment tends to decrease rather than increase posthospitalization, with proportions of patients on appropriate therapy declining over time and patients not reaching risk factor targ”
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management (2011, background): “Thus, the risk associated with elevated triglycerides can be explained by this lipid acting as a marker for increased numbers of TRL, which in turn are closely associated with the combination of higher levels of non-HDL-C and low levels of HDL-C.”
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. (2016, background): “7 mmol/L (150 mg/dL).(258) HTG can have different causes (Table 17), among which its polygenic nature is most important in relation to CVD prevention.”
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). (2011, background): “7 mmol/L (more than 150 mg/dL).(122) HTG can have different causes (Table 15).”